{"paper_id":"6f56c566-5917-4394-aab1-f1b8b140ebb6","body_text":"Page 1/28\nThe NLRP3 activation-related signature predict the\ndiagnosis and indicate immune characteristics in\nendometriosis\nWeihua Nong \nThe Aliated Hospital of Youjiang Medical University for Nationalities\nHuimei Wei \nThe Aliated Hospital of Guilin Medical University\nSheng Dou \nGuangxi Medical and health key discipline construction project of the Aliated Hospital of Youjiang\nMedical University for Nationalities\nLiqiao He \nThe Aliated Hospital of Youjiang Medical University for Nationalities\nTianlong Li \nUniversity of South China\nLuping Lin \nThe Aliated Hospital of Youjiang Medical University for Nationalities\nBixiao Wei \nThe People’s Hospital of Baise\nShun Zhang \nThe Aliated Hospital of Guilin Medical University\nPeng Huo \nGuilin Medical University\nMingyou Dong  (  mydong@ymun.edu.cn )\nGuangxi Medical and health key discipline construction project of the Aliated Hospital of Youjiang\nMedical University for Nationalities\nResearch Article\nKeywords: Endometriosis, GEO, Diagnostic marker, Nomogram, Immune cells inltration\nPosted Date: May 3rd, 2023\nDOI: https://doi.org/10.21203/rs.3.rs-2830815/v1\n\nPage 2/28\nLicense:   This work is licensed under a Creative Commons Attribution 4.0 International License.  \nRead Full License\n\nPage 3/28\nAbstract\nEndometriosis (EMS) is a common gynecological disease leading to chronic pelvic pain and infertility in\nwomen of reproductive age, but its underlying pathogenic genes and effective treatment are still unclear.\nTo date, abnormal expression of NLRP3 activation-related genes has been identied in EMS patients and\nmouse models. Therefore, this study sought to identify the key genes that could affect the diagnosis and\ntreatment of EMS. The GSE7307 dataset was downloaded from the Gene Expression Omnibus (GEO)\ndatabase, including 18 EMS samples and 23 control samples. 14 differential genes related to NLRP3\nactivation and EMS were obtained from the endometrial samples of GSE7307 by differential analysis. GO\nand KEGG analysis showed that these genes were mainly involved in the production and regulation of the\ncytokine IL-1 β , and the NOD-like receptor signaling pathway. Random Forest (RF) and support vector\nmachine recursive feature elimination (SVM-RFE) algorithms were used to select four diagnostic markers\nrelated to NLRP3 activation (NLRP3, IL-1 β , LY96 and PDIA3) to construct the EMS diagnostic model. The\nfour diagnostic markers were veried using western blotting and validated in the GSE7305 and\nGSE23339 datasets. The AUC values showed that the model had a good diagnostic performance. In\naddition, the inltration of immune cells in the samples and the correlation between different immune\nfactors and diagnostic markers were further discussed. These results suggest that four diagnostic\nmarkers may also play an important role in the immunity of EMS. Finally, 10 drugs targeting to four\ndiagnostic markers were retrieved from the DrugBank database, of which niclosamide proved useful for\ntreating EMS. Overall, we identied four key diagnostic genes for EMS. In addition, large-scale and\nmulticenter prospective cohort studies are necessary to conrm whether these four genes also have valid\ndiagnostic value in blood samples from EMS patients.\nIntroduction\nEndometriosis (EMS) is a chronic inammatory disease dened as the presence of endometrial tissue\noutside the uterus, causing pelvic pain and infertility, affecting 5–10% of women of reproductive age\nworldwide[1, 2]. The most prevalent theory of the origin of endometriosis, advanced by Sampson (1928),\nholds that during menstruation, endometrial cells and tissue fragments return through the fallopian tubes,\nsurvive, attach and invade pelvic structures[3]. Depending on the location of the disease, EMS is\nclassied as supercial (or peritoneal), ovarian (endometrioma), and deep (dened as invasive lesions\ngreater than 5 mm in depth). The diagnosis of EMS is made primarily through laparoscopy, based on an\nempirically guided clinical decision based on history, symptoms, clinical examination, and imaging,\nwhereas biochemical markers lack sensitivity and specicity[4, 5]. Therefore, it is necessary to explore the\nunderlying molecular mechanism and nd new markers to provide more meaningful and reliable\ndiagnostic information for EMS treatment, so as to promote early diagnosis and individualized treatment.\nNod-like receptor protein 3 (NLRP3) is a component of the inammasome that activates caspase1,\npromoting the processing of IL-1 β  and IL-18 into biologically active mature forms and inducing\npyroptosis[6, 7]. Furthermore, NLRP3 inammasome-mediated pyroptosis has been reported to play a\ncrucial role in the pathogenesis of inammatory diseases[8, 9]. EMS is also a chronic inammatory\n\nPage 4/28\ndisease, and previous studies have also reported an association between NLRP3 inammasome and the\nprogression of EMS[10, 11]. A study has reported that targeted inhibition of NLRP3 can inhibit the\nproduction of IL-1 β  and cell proliferation in EMS, thereby improving ovarian function in EMS[12]. Estrogen\nreceptor(ER) β  has been reported to interact with components of the inammasome in endometriotic cells,\nincreasing interleukin-1 β  to enhance their cell adhesion and proliferative properties, thereby increasing the\ninvasive activity of endometrial tissues to establish ectopic lesions[13]. Due to the non-negligible\nrelationship between NLRP3 activation and EMS, it is necessary to explore the specic role of NLRP3\nactivation-related features in EMS and identify more diagnostic biomarkers.\nIn this study, we conducted a systematic study of NLRP3 activation-related genes to explore the\ndifferential expression of these genes in EMS patients and normal controls and to construct an effective\ndiagnostic nomogram model for clinical application. Inammation is a vital pathological feature of EMS,\nwhich is closely related to immune function. Therefore, we further explored the immune penetration of\nthese samples and the correlation between different immune factors and these diagnostic biomarker\ncandidates. In addition, ten drugs targeting these diagnostic biomarker candidates were retrieved from\nthe DSigDB database, which has implications for the pharmacotherapy of EMS. Therefore, this study\nprovides potential targets for the diagnosis and treatment of EMS. The workow of this study is shown in\nFig. 1.\nMaterials and Methods\nData acquisition\nFirst, the three datasets, GSE7307 (including 18 EMS samples and 23 normal samples) ,  GSE7305\n(including 10 EMS samples and 10 normal samples), and GSE23339 (including 10 EMS samples and 9\nnormal samples ) were downloaded from Gene Expression Omnibus (GEO) database. The data\nprocessing steps are as follows: (1) match multiple probes to the same gene, (2) remove the null probes,\n(3) rst match probes to genes, and (4) log2 transformation of the obtained data set. The number of bits\nused to normalize signal strength.\nDEGs in EMS\nGene expression difference data between EMS samples and normal samples were examined by using a\nlimma package in R and using a threshold with a modied P value of 0.05 or less.\nFunctional enrichment analysis of the DEGs\nTo explore the biological mechanism of differentially expressed genes (DEGs) affecting EMS, a\nfunctional enrichment analysis was carried out. First, the “clusterProler” and “ggplot2” packages were\nemployed for Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) was used\n\nPage 5/28\nfor enrichment analyses of DEGs[14]. Adjusted P < 0.05 had signicance in statistics. Subsequently, Gene\nSet Enrichment Analysis (GSEA) that used the ‘Clusterproler’ R package to perform revealed the\nrespective function of each key gene. The samples were divided into low-expression groups and high-\nexpression groups according to median values of the expression levels in key genes. The genes were\nsorted from highest to lowest by logFC, and the rst 5 and last 5 GSEA results were taken after sorting.\nThese gene sets were downloaded from the Molecular Signature Database (MSigDB, https://www.gsea-\nmsigdb.org/gsea/msigdb/ index.jsp). The nal result is displayed in the \"enrichplot\" package of the R\nsoftware. P-values < 0.05 was considered to be statistically signicant.\nScreening for candidate diagnostic biomarkers\nDiagnostic markers of EMS were classied using random forest (RF) and support vector machine\nrecursive feature elimination (SVM-RFE) arithmetic methods. The  RF algorithm randomizes a single\ndecision tree overtting reduction algorithm and improves model accuracy based on many related\ndecision trees in the training set[15]. SVM-RFE as a support vector monitoring machine learning method\nidenties optimal variables via the deletion of the SVM-produced eigenvectors[16]. Markers selected for\nEMS diagnosis were classied and analyzed using the SVM classier in the R package e1071.\nVerication of the diagnostic biomarker results\nEndometrium from endometriosis patients or matched control patients came from the Aliated Hospital\nof Youjiang Medical College for Nationalities, Baise, China. We collected 12 cases diagnosed as ovarian\nendometriosis cysts (n=6) and non-endometriosis (n=6) with inclusion conditions: ageg between 26 and\n46 years, BMI of 21-27 kg/m2, non-vegetarian patients, no contraindications for surgery; The exclusion\ncriteria were endocrine diseases such as diabetes, and severe gastrointestinal, heart, lung, and liver\ndiseases. All the donors did not take drugs and hormones before surgery, and underwent combined\nuterine and abdominal surgery at the same time due to abnormal uterine bleeding. All tissue samples\nwere obtained from tissue resected during surgery and were approved and informed by the patient and\nthe ethics review committee of our hospital. Protein preparation and western blotting were performed as\ndescribed previously[17]. Endometrial tissue lysates (500 μ L in RIPA lysis buffer  PMSF= 94:6) were\nprocessed for western blotting, where protein concentrations were determined with BCA Protein Assay Kit.\nThen, proteins were denatured by boiling at 100 °C for 10 min. SDS-PAGE was conducted with denatured\nprotein samples of approximately 20 μ g loaded onto a 10% Tris–acetate gel, run at 120 V for 2 h.\nProteins in the gel were transferred onto polyvinylidene uoride membranes at 300 mA for 50 min, and\nblocked in PBST containing 5% skim milk powder for 2 h. After washing with PBST, the membranes were\nrespectively incubated with antibodies against NLRP3 (1:1000 dilution, bs-10021R; Bioss, Beijing, China),\nLY96 (1:1000 dilution, 11784-1-AP; proteintech, Wuhan, China), IL-1 β  (1:3000 dilution, 26048-1-\nAP; proteintech), PDIA3 (1:8000 dilution, 15967-1-AP; proteintech), and TUBULIN (1:20000 dilution, 66031-\n1-Ig; proteintech) overnight at 4 °C, and washed with PBST three times for 10  min each. It was then\nincubated for 2 h at room temperature with a goat anti-rabbit IgG (1:5000 dilution, SA00001-\n\nPage 6/28\n2; proteintech) and a goat anti-mouse IgG (1:5000 dilution, SA00001-1; proteintech) horseradish\nperoxidase (HRP)-conjugated secondary antibody. After three 10-min washes of the membrane in PBST,\neECL was added, and the Tanon-5500 Chemiluminescence Imaging System was used to detect the\nchemiluminescence of protein bands. \nDiagnostic value of the key genes in EMS\nThe generalized linear model (GLM), support vector machine model (SVM), extreme gradient boosting\nmodel (XGB), and random forest model (RF) were performed based on the combined training dataset.\nThe four models were analyzed using the interpretation function of DALEX package in R, and the residual\ndistribution was performed to obtain the optimal model. We constructed ROC curves to examine the\npredictive utility of the proposed biomarkers by using mRNA expression data from 23 normal samples\nand 18 EMS samples. EMS and control samples were separated by ROC analysis and further validated in\nGSE7305 and GSE23339 datasets.\nDistribution of the immune cells\nThe CIBERSORT (http://cibersortx.stanford.edu) algorithm was used to calculate the relative proportions\nof the 22 immune cell types in the training dataset samples.\nAnalysis of genes identied and immune cells inltrated\nSpearman rank correlation analysis was used to determine the correlation between the four key\ndiagnostic genes and the number of inltrating immune cells. The graph method of the ggplot2 package\nis used to show the correlation of results.\nConstruction of nomogram and diagnostic score model\nFirst, a nomogram model for predicting the occurrence of EMS was constructed using the rms package\n(version 5.1-2)[18]. Then, the calibration curve was constructed to assess the diagnostic power of\nthe nomogram model. Finally, the clinical value of the nomogram model was evaluated by using decision\ncurve analysis (DCA).\nPrediction of potential drug compounds\nThe Drug Signature Database (DSigDB) was used to screen potential drug molecules with gene-based\ninteractions. As a public web-based database derived from an enrichment web server, DSigDB provides\ninformation about drugs and their target genes for GSEA[19]. Based on a statistical threshold of adjusted\n\nPage 7/28\np-value < 0.05, we identied protein-drug interactions in the EMS-pyroptosis interaction that may affect\nimportant central genes.\nStatistical analysis.\nAll analyses were performed in R program 4.0.2. The t-test and the Mann-Whitney U-test were chosen\nbased on whether the data t a normal distribution. The Spearman correlation method was used to study\nthe relationship between the expressions of diagnostic genes and inltration immunocytes. P values <\n0.05 was considered statistically signicant.\nResults\nDetermination of DEGs in EMS\nTo investigate DEGs of EMS, we examined the GSE7307 dataset and identied 14 DEGs in EMS, including\n11 up-regulated genes (CASP1, IL10, IL17RA, IL1B, IL1R1, IL6, LY96, NLRP3, P2RX7, PIK3CA and TLR4)\nand 3 down-regulated genes (EIF2AK3, HMGB1 and PDIA3) (Fig. 2A and 2B).\nEnrichment analysis of biological process and pathway\nGO analysis results showed that DEGs were mainly rich in positive regulation of cytokine production,\ncellular response to biotic stimulus, cellular response to lipopolysaccharide, cellular response to molecule\nof bacterial origin, response to lipopolysaccharide, interleukin-1 production, regulation of interleukin-1\nproduction, positive regulation of interleukin-1 beta production, positive regulation of interleukin-1\nproduction, and regulation of cytokine production involved in the immune response (Fig. 3A). KEGG\nassays revealed that DEGs were mainly enriched in the NOD-like receptor signaling pathway (Fig. 3B). \nDetection and verication of diagnostic genes in EMS\nTwo machine learning methods were applied in selecting potential markers of EMS: SVM-RFE and RF.\nWe rst screened 14 DEGs with SVM-RFE analysis and identied 10 diagnostic biomarkers (Fig. 4A). RF\nanalysis identied 4 diagnostic biomarkers from 14 DEGs (Fig. 4B and 4C). After integrating the\ncharacteristic genes from SVM-RFE and RF, four characteristic genes closely related to pyroptosis were\nobtained: NLRP3, IL-1 β , LY96, and PDIA3 (Fig. 4D). The expression of NLRP3, IL-1 Β , and LY96 was\ndistinctly upregulated in EMS, and the expression of PDIA3 was distinctly upregulated in EMS (Fig. 5A).\nThe diagnostic value of four overlapping genes was shown by the use of ROC assays (Fig. 5B). We\nveried the results of the screened differential genes at the protein level. The verication results revealed\nthat the protein (Fig. 6A and 6B) levels of NLRP3 (P<0.05), LY96 (P<0.01) and IL-1 β  (P<0.05) in EMS were\nhigher than those in the control group, while the results of PDIA3 (P>0.05) were the opposite, consistent\n\nPage 8/28\nwith the Gene Chip data with multiple exposures. Moreover, we further determined the diagnostic value of\nNLRP3, IL-1 β , LY96 and PDIA3 in the GSE7305 and GSE23339 datasets, and the results are shown in Fig.\n7. We established the RF, SVM, XGB, and GLM models to choose NLRP3 activation-related genes to\npredict the incidence of EMS. Both “Reverse Cumulative Distribution of Residual” (Fig. 8A) and “Boxplots\nof Residual” (Fig. 8B) indicate that the GLM model has minimal residuals. The ROC curve was drawn to\nevaluate the model, and the AUC value of the ROC curve also indicated that the GLM model had higher\naccuracy compared with the other three models (Fig. 8C). Finally, the ROC curve also demonstrated the\ngood diagnostic performance of the four genetic biomarker combinations based on the four\nclassication models in both validation datasets (GSE7305 and GSE23339) for normal women and EMS\npatients. (Fig. 8D and 8E).\nAnalysis of functional correlations\nGene set enrichment analysis (GSEA) was performed for the four key genes based on the median\nexpression prole. GSEA expression analysis of four genes in NLRP3 showed that the gene expressions\nof malaria, pertussis, systemic lupus erythematosus immune-related diseases and biological processes\nof complement and coagulation cascades and taurine and hypotaurine metabolism were signicantly\nincreased in the high expression group, while base excision repair, DNA replication, Fanconi anemia\npathway, homologous recombination, and mismatch repair in the low expression group (Fig. 9A). The IL-\n1 β  in the high expression group were signicantly enriched in the legionellosis, malaria, systemic lupus\nerythematosus, complement and coagulation cascades, and viral protein interaction with cytokine and\ncytokine receptor, whereas those in the low-expression groups were signicantly enriched in\naminoacyl−tRNA biosynthesis, base excision repair, DNA replication, homologous recombination, and\nmismatch repair (Fig. 9B). The LY96 in the high-expression group was signicantly enriched in asthma,\nlegionellosis, malaria, systemic lupus erythematosus, and complement and coagulation cascades. On the\nother hand, LY96 in the low expression groups was signicantly enriched in base excision repair, DNA\nreplication, Fanconi anemia pathway, homologous recombination, and mismatch repair (Fig. 9C).\nUltimately, the PDIA3 in the high expression group was signicantly enriched in DNA replication, Fanconi\nanemia pathway, homologous recombination, mismatch repair, and protein export, nevertheless, those in\nthe low expression group were signicantly enriched in asthma, malaria, pertussis, systemic lupus\nerythematosus, and taurine and hypotaurine metabolism (Fig. 9D).\nCorrelation between four diagnostic genes and EMS\nimmune permeation level\nIn this study, the proportion of 21 immune cells in 18 EMS samples and 23 Normal samples was\nestimated with the CIBERSORT algorithm, which can be seen in the histograms. The abundance of B cells\nmemory, Plasma cells, T cells CD4 memory resting, Macrophages M2, Mast cells activated, and\nEosinophils were higher in EMS samples than that in normal samples, while the inltration abundance of\n\nPage 9/28\nB cells naïve, NK cells activated, and Mast cells resting in EMS samples were lower (Fig. 10A and 10B).\nFour biomarkers (NLRP3, IL-1 β , LY96 and PDIA3) were associated with 6 signicantly different immune\ncells in 21 immune cell types, including Dendritic cells activated, Dendritic cells resting, Eosinophils,\nMacrophages M1, Monocytes, and Plasma cells (Fig. 10C and 10D). As shown in Figure 9D, NLRP3 was\nnegatively correlated with B cells naïve only. IL-1 β  was positively correlated with Plasma cells but\nnegatively correlated with Mast cells resting and T cells CD4 naïve. LY96 was related to Plasma cells,\nMacrophages M2, B cells mEMSory, T cells gamma delta, and Eosinophils in a positive way, while\nnegatively related with B cells naïve, NK cells activated, Dendritic cells activated, Mast cells resting, T cells\nCD8, and T cells follicular helper. PDIA3 has positively correlated with T cells CD4 memory activated\nwhen negatively correlated with B cells memory and Macrophages M2.  \nConstruction and assessment of the diagnostic nomogram\nmodel\nA nomogram was created to validate the diagnostic power of the four EMS biomarkers (Fig. 11A). The\ncalibration curve showed a small error between the actual EMS risk and the predicted risk, indicating that\nthe nomogram model had a high accuracy in predicting EMS (Fig. 11B). DCA showed that the nomogram\ncurve was higher than the gray critical line and the four biomarker curves, indicating that the nomogram\nmodel had the best clinical benet (Fig. 11C). \nIdentication of candidate pharmacologic agents\nFour well-validated diagnostic genes (NLRP3, IL-1 β , LY96, and PDIA3) were used as genetically linked\ntargets to facilitate further studies in therapeutic development by a drug target enrichment analysis was\nperformed (Table 1). We have listed the top 10 candidate enrichment agents targeting gene links, which\nmay be targeted for the development of co-onset therapeutic strategies. Studies have shown that\nniclosamide can target and inhibit macrophage-induced endometriosis inammatory microenvironment,\nthereby improving reproductive function[20–22]. In addition, our analysis of the results based on Table 1\nindicates that niclosamide is considered a candidate molecule for the treatment of EMS because of its\nhigh odds ratio and high composite score.\nDiscussion\nEndometriosis, a gynecological disease characterized by the implantation of endometrial tissue outside\nthe uterus, has attracted increasing attention worldwide recently. However, despite its prevalence,\ndiagnosis is often delayed by years, misdiagnosis is common, clinical presentations are varied, and the\npresence of pelvic lesions is heterogeneous[1]. Currently, EMS is usually treated with a combination of\nhormone therapy and surgery to remove the lesion[23]. Despite recent advances in the medical treatment\nof endometriosis-related pelvic pain, there are still no drugs available to treat the condition[24]. Therefore,\n\nPage 10/28\nthe identication of novel molecular factors and the unraveling of the underlying mechanisms of EMS\nwill facilitate early diagnosis and the development of effective therapies.\nIn the present study, we identied DEGs across the GSE7307 dataset including 18 EMS samples and 23\nnormal samples. These DEGs included 11 upregulated and 3 downregulated genes, respectively. GO and\nKEGG analyses revealed that these DEGs were involved in regulating immune-related signaling pathways,\nsuch as the production and regulation of the cytokine IL-1 β , as well as the NOD-like receptor signaling\npathway. We applied the machine learning methods of SVM-RFE and RF to integrate the feature genes\nand obtained four feature genes: NLRP3, IL-1 β , LY96 and PDIA3. Then, we further conrmed their\ndiagnostic using GSE7305 and GSE23339 datasets, and further demonstrated NLRP3, IL-1 β , LY96 and\nPDIA3 as critical biomarkers for EMS based on the results of ROC assays.\nThe inammasome is newly discovered and plays an important role in innate immunity. The most typical\nis the NLRP3 inammasome, the so-called NLRP3 protein because the NLRP3 protein in this complex\nbelongs to the family of nucleotide-binding and oligomerization domain-like receptors (NLRs), also\nknown as \"pyrin domain-containing protein 3\"[25]. The expression of NLRP3 in EMS tissues and serum of\nEMS patients was higher than that of normal controls, which contributed to the invasion of EMS[26].\nSince EMS is a gynecologic disorder associated with estrogen, higher estrogen receptor (ER)- β  levels and\nenhanced ER- β  activity are detected in endometriotic tissues. ER- β  is known to interact with NALP3, and\nthe activation of NALP3 increases interleukin IL-1 β  and IL-18, thereby enhancing cell adhesion and\nproliferation[27]. The NLRP3 inhibitor (MCC950) has recently been reported to signicantly reduce the co-\nlocalization of NLRP3 and IL-1 β  in cyst-derived stromal cells (CSCs) and IL-1 β  concentration in the\nsupernatant of CSCs. Thereby contributing to Ovarian endometriosis (OE) suppression and improving\novarian function in endometriosis[12]. However, the specic mechanism of NLRP3 in EMS is still unclear.\nIL-1 β  plays a considerable role in inammatory diseases and the main sources of its secretion are\nmacrophages and monocytes, dendritic cells (DC), B lymphocytes, neutrophils and natural killer (NK) cells\nand non-immune cells such as keratinocytes[28]. The maturation of IL-1 β  and IL-18 induces pyroptosis, a\nform of cell death[29]. The inammatory factor IL-1 β  has been reported to be signicantly increased in\nectopic endometrial tissue of patients with EMS[30], which is consistent with our results. Chronic pelvic\npain is one of the main clinical symptoms of female endometriosis, but its specic mechanism is unclear.\nIL-1 β  is closely related to inammatory pain by sending inammatory pain signals to the hypothalamus\nand participating in afferent pain response[31]. A retrospective study of peritoneal uid samples obtained\nby laparoscopy found an increase in IL-1 β  concentration compared with normal controls that were\nstatistically signicant only in women with endometriosis who reported pelvic pain[32]. In addition, some\nstudies have revealed the mechanism of deep dyspareunia in endometriosis, that is, IL-1 β  stimulates the\nexpression of nerve growth factor (NGF), promotes local neurogenesis around endometriosis, and then\nleads to tenderness in the pelvic anatomy, leading to deep dyspareunia[33]. Because IL-1 β  can induce\nNGF expression and increase NGF bioactivity, dienogest, a selective P-receptor (PR) agonist, Inhibition of\nNGF expression by PR-A and PR-B in human endometrial epithelial cells (hEECs) may contribute to the\nrelief of endometriosis pain[34]. Sulforaphane alleviates pain caused by sciatic nerve endometriosis,\n\nPage 11/28\nwhich is mediated by the inhibition of inammatory cytokines IL6, IL-1 β , and TNF- α [35]. Overall,\npharmacological targeting of IL-1 β /NGF may also have the potential for the treatment of endometriosis-\nrelated pain.\nLY96 plays a crucial role in inammation-related and immune-related diseases, such as Crohn's disease,\nrheumatoid arthritis, and inammatory diabetic cardiomyopathy[36]. Key protein disulde isomerase 3\n(PDIA3) is a kind of chaperone, that can adjust the folding of the new synthesis glycoprotein, the\nheterogeneous and REDOX enzyme activity, and immune activation marks, cancer immune cells and\nimmune modulators signicantly related, is a powerful cancer prognosis biomarkers, which can\neffectively predict the immune response to treatment[37, 38]. Similarly, the expression and function of\nLY96 and PDIA3 in EMS remain are largely unknown.\nFurthermore, we also evaluated the degree of inltration of 22 immune cells in EMS and normal samples.\nCompared with normal samples, EMS samples had distinctly higher levels of B cells memory, Plasma\ncells, T cells CD4 memory resting, Macrophages M2, Mast cells activated, and Eosinophils. It is well\nknown that endometriosis lesions are characterized by the presence of numerous plasma cells and\nactivated macrophages[39]. One study found that the relative abundance of resting CD4 + memory T cells\nand even less abundant memory B cells were signicantly higher in patients with stage III/IV\nendometriosis, which was strongly associated with endometrial receptivity[40]. Activated macrophages\nare generally divided into two groups, M1-like macrophages and M2-like macrophages, both of which are\nclosely related to the inammatory response[41]. Another study found a signicant increase in total\nmacrophages in ectopic endometrial tissue (EC) and a syngeneic mouse model of endometriosis, and M2\nmacrophages were the predominant macrophages in EC[42, 43]. Of note, M2 macrophages have been\nfound to increase gradually from stage I to stage IV in ectopic endometrial tissues of EMS patients,\nwhereas M1 macrophages have been found to increase in contrast, which may contribute to the\nproinammatory microenvironment in the early stage of the disease, as well as to the probrotic activity\nin the late stage[44]. Diffuse inltration of large numbers of mast cells (MCs) is observed in the\ninterstitium of ectopic endometrial tissues of EMS. MCs promote the development of endometriosis\nthrough NLRP3 inammasome activation mediated by nuclear-initiated estrogen signaling pathway and\nthe production of mature IL-1 β [45, 46]. In addition, the preoperative pain score of EMS is closely related to\nthe density and number of mast cells, and the use of MCs stabilizers and inhibitors can relieve\nendometriosis and its associated pain[47, 48]. Eosinophils can regulate broblasts and stimulate\ncollagen synthesis. Eosinophils are abundant in brotic areas and peritoneal uid of endometriosis,\nwhich is associated with brosis of endometriosis lesions[49, 50]. Moreover, we found that the\nexpressions of NLRP3, IL-1 β , LY96, and PDIA3 were related to the levels of many immune cells,\nhighlighting their potential used as therapeutic targets for EMS. Hence, The differential expression of\nNLRP3, IL-1 β , LY96, and PDIA3 between EMS and normal groups pointed out they might be crucial\nimmune-related biomarkers to diagnose EMS. A diagnostic nomogram model based on four core genes\nwith excellent predictive power was established, and patients would benet from this model.\n\nPage 12/28\nFinally, based on four diagnostic genes as gene junction points, we identied niclosamide as a candidate\nmolecule for EMS treatment due to its high odds ratio and high comprehensive score among the top 10\ncandidate enrichment agents by drug target enrichment analysis. Niclosamide was discovered in 1953 at\nthe Bayer Chemotherapy Research Laboratory to treat tapeworm infections in humans and is listed on the\nWorld Health Organization's Essential Medicines List[51]. However, accumulating evidence suggests that\nniclosamide is a multifunctional drug capable of inhibiting or modulating multiple signaling pathways\nand biological processes, which has been demonstrated to treat endometriosis in vitro and in vivo\nexperiments. Recent niclosamide was reported can effectively reduce the endometriosis of endometriosis\nlesions in mice (ELL) induced by peritoneal macrophages (LPM) and LPM the expression of related\ngenes, and by reducing ELL and pelvic organs may stimulate the peripheral nerve as a medium of\ninammatory factor to reduce the abnormal inammation, may eventually reduce the pain\nassociated[52]. In the endometriosis model in mice, chlorine nitramine can not only through targeted\nSTAT3 and NFkB signaling pathways, reduce the growth and progress of the sample endometriosis\nlesions, but also can inhibit the inammatory mechanisms, thereby reducing the macrophages induced\ncell activity and the secretion of cytokine/chemokine based on not affect reproductive function[20–22].\nAt present, although niclosamide has not been used in the clinical treatment of endometriosis, the results\nof previous studies and our results suggest that niclosamide may be a novel strategy for the targeted\ntreatment of inammatory dysfunction in endometriosis.\nConclusion\nFour diagnostic genes related to NLRP3 activation and EMS were identied by bioinformatics. Although\nwe have explored the biological processes and pathways involved in them, further experimental\nverication is needed to verify these functions. The nomogram based on these four genes has a good\ndiagnostic effect on EMS, which provides a theoretical basis for clinical diagnosis. In addition, these\ndiagnostic genes were found to be associated with different immune factors, suggesting that they may\nalso have important roles in the immune microenvironment. Currently, drugs targeting these pyroptosis\ngenes are predicted to alleviate EMS, but only niclosamide has the results of basic studies to support its\nuse in the treatment of EMS, and further studies are needed to explore its specic mechanism of action.\nFirstly, the GSE7307 dataset was downloaded from the GEO database, including 18 EMS samples and 23\ncontrol samples. The nal 14 DEGs related to pyroptosis and EMS were obtained from the endometrial\nsamples of GSE7307 by differential analysis. GO and KEGG analysis showed that these genes were\nmainly involved in two major biological processes. Random Forest (RF) and support vector machine\nrecursive feature elimination (SVM-RFE) algorithms were used to select four genes to construct the EMS\ndiagnostic model. The model was validated in endometrial samples of GSE7305 and GSE23339, and the\nAUC values showed that the model had a good diagnostic performance. In addition, the inltration of\nimmune cells in the samples and the correlation between different immune factors and pyroptosis genes\nwere further discussed. These results suggest that these diagnostic genes may also play an important\nrole in the immunity of EMS. Finally, 10 drugs targeting these four diagnostic genes were retrieved from\nthe DrugBank database, of which niclosamide proved useful for treating EMS. Overall, we identied four\n\nPage 13/28\nkey diagnostic genes for EMS. In addition, large-scale and multicenter prospective cohort studies are\nnecessary to conrm whether these four genes also have valid diagnostic value in blood samples from\nEMS patients.\nDeclarations\nAcknowledgements\nNone.\nAuthors’ contributions\nMD and PH directed the study; WN, HW and SD performed the experiments; LH, TL, LL and BW performed\nthe data collection and statistical analysis; SZ edited the language; all the authors approved the\nmanuscript for submission.\nFunding\nThis research was supported by the National Natural Science Foundation of China (No. 81960274), the\n2020 university-level Research Project of Youjiang Medical University for Nationalities (No.\nyy2020gcky039), and the 2021 Scientic Research and Technology Development Program of Baise City\n(No. 20212351).\nAvailability of data and materials\nPublicly available datasets were analyzed in this study. This data can be found here: All the raw data\nused in this study are derived from the public GEO data portal (https://www.ncbi.nlm.nih.gov/geo/;\nAccession numbers: GSE7307, GSE7305 and GSE23339).\nEthics approval and consent to participate\nAll procedures were approved by the ethics review committee of Aliated Hospital of Youjiang Medical\nCollege for Nationalities.  All methods were carried out in accordance with relevant guidelines and\nregulations of the ethics review committee of Aliated Hospital of Youjiang Medical College for\nNationalities, and informed consent was obtained from all subjects and/or their legal guardian(s).\nConsent for publication\nNot applicable.\nCompeting interests\nThe authors declare that they have no competing interests.\n\nPage 14/28\nReferences\n1. Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical challenges\nand novel innovations. Lancet. 2021;397:839–52.\n2. Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management\nof endometriosis. Nat Rev Endocrinol. 2019;15:666–82.\n3. Vallvé-Juanico J, Houshdaran S, Giudice LC. The endometrial immune environment of women with\nendometriosis. Hum Reprod Update. 2019;25:564–91.\n4. Koninckx PR, Fernandes R, Ussia A, Schindler L, Wattiez A, Al-Suwaidi S, et al. Pathogenesis Based\nDiagnosis and Treatment of Endometriosis. Front Endocrinol (Lausanne). 2021;12:745548.\n5. Kiesel L, Sourouni M. Diagnosis of endometriosis in the 21st century. Climacteric. 2019;22:296–302.\n. Humphries F, Bergin R, Jackson R, Delagic N, Wang B, Yang S, et al. The E3 ubiquitin ligase Pellino2\nmediates priming of the NLRP3 inammasome. Nat Commun. 2018;9:1560.\n7. Beckerman P, Bi-Karchin J, Park ASD, Qiu C, Dummer PD, Soomro I, et al. Transgenic expression of\nhuman APOL1 risk variants in podocytes induces kidney disease in mice. Nat Med. 2017;23:429–38.\n. Wang L, Hauenstein AV. The NLRP3 inammasome: Mechanism of action, role in disease and\ntherapies. Mol Aspects Med. 2020;76:100889.\n9. Zhao K, An R, Xiang Q, Li G, Wang K, Song Y, et al. Acid-sensing ion channels regulate nucleus\npulposus cell inammation and pyroptosis via the NLRP3 inammasome in intervertebral disc\ndegeneration. Cell Prolif. 2021;54:e12941.\n10. Hang Y, Tan L, Chen Q, Liu Q, Jin Y. E3 ubiquitin ligase TRIM24 deciency promotes NLRP3/caspase ‐\n1/IL ‐ 1 β ‐ mediated pyroptosis in endometriosis. Cell Biology International. 2021;45:1561–70.\n11. Zhou F, Zhao F, Huang Q, Lin X, Zhang S, Dai Y. NLRP3 activated macrophages promote endometrial\nstromal cells migration in endometriosis. Journal of Reproductive Immunology. 2022;152:103649.\n12. Murakami M, Osuka S, Muraoka A, Hayashi S, Bayasula  null, Kasahara Y, et al. Effectiveness of\nNLRP3 Inhibitor as a Non-Hormonal Treatment for ovarian endometriosis. Reprod Biol Endocrinol.\n2022;20:58.\n13. Han SJ, Jung SY, Wu S-P, Hawkins SM, Park MJ, Kyo S, et al. Estrogen Receptor β  Modulates\nApoptosis Complexes and the Inammasome to Drive the Pathogenesis of Endometriosis. Cell.\n2015;163:960–74.\n14. Yu G, Wang L-G, Han Y, He Q-Y. clusterProler: an R package for comparing biological themes among\ngene clusters. OMICS. 2012;16:284–7.\n15. Gers FA, Schmidhuber E. LSTM recurrent networks learn simple context-free and context-sensitive\nlanguages. IEEE Trans Neural Netw. 2001;12:1333–40.\n1. Huang S, Cai N, Pacheco PP, Narrandes S, Wang Y, Xu W. Applications of Support Vector Machine\n(SVM) Learning in Cancer Genomics. Cancer Genomics Proteomics. 2018;15:41–51.\n\nPage 15/28\n17. Liang A, Huang L, Liu H, He W, Lei X, Li M, et al. Resveratrol Improves Follicular Development of\nPCOS Rats by Regulating the Glycolytic Pathway. Mol Nutr Food Res. 2021;e2100457.\n1. Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16:385–95.\n19. Yeoh YK, Zuo T, Lui GC-Y, Zhang F, Liu Q, Li AY, et al. Gut microbiota composition reects disease\nseverity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70:698–706.\n20. Sekulovski N, Whorton AE, Shi M, MacLean JA, Hayashi K. Endometriotic inammatory\nmicroenvironment induced by macrophages can be targeted by niclosamide † . Biol Reprod.\n2019;100:398–408.\n21. Prather GR, MacLean JA, Shi M, Boadu DK, Paquet M, Hayashi K. Niclosamide As a Potential\nNonsteroidal Therapy for Endometriosis That Preserves Reproductive Function in an Experimental\nMouse Model. Biol Reprod. 2016;95:76.\n22. Sekulovski N, Whorton AE, Tanaka T, Hirota Y, Shi M, MacLean JA, et al. Niclosamide suppresses\nmacrophage-induced inammation in endometriosis † . Biol Reprod. 2020;102:1011–9.\n23. Suryawanshi S, Huang X, Elishaev E, Budiu RA, Zhang L, Kim S, et al. Complement pathway is\nfrequently altered in endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res.\n2014;20:6163–74.\n24. Moses AS, Taratula OR, Lee H, Luo F, Grenz T, Korzun T, et al. Nanoparticle-Based Platform for\nActivatable Fluorescence Imaging and Photothermal Ablation of Endometriosis. Small.\n2020;16:e1906936.\n25. Shao B-Z, Xu Z-Q, Han B-Z, Su D-F, Liu C. NLRP3 inammasome and its inhibitors: a review. Front\nPharmacol. 2015;6:262.\n2. Huang Y, Li R, Hu R, Yao J, Yang Y. PEG2-Induced Pyroptosis Regulates the Expression of HMGB1\nand Promotes hEM15A Migration in Endometriosis. Int J Mol Sci. 2022;23:11707.\n27. Di Nicuolo F, Castellani R, De Cicco Nardone A, Barbaro G, Paciullo C, Pontecorvi A, et al. Alpha-Lipoic\nAcid Plays a Role in Endometriosis: New Evidence on Inammasome-Mediated Interleukin\nProduction, Cellular Adhesion and Invasion. Molecules. 2021;26:E288.\n2. Wenjing F, Tingting T, Qian Z, Hengquan W, Simin Z, Agyare OK, et al. The role of IL-1 β  in aortic\naneurysm. Clin Chim Acta. 2020;504:7–14.\n29. He Y, Hara H, Núñez G. Mechanism and Regulation of NLRP3 Inammasome Activation. Trends\nBiochem Sci. 2016;41:1012–21.\n30. J H, X C, Y L. HMGB1 Mediated Inammation and Autophagy Contribute to Endometriosis. Frontiers\nin endocrinology [Internet]. Front Endocrinol (Lausanne); 2021 [cited 2022 Oct 16];12.\n31. Wang W, Li G, De Wu  null, Luo Z, Pan P, Tian M, et al. Zika virus infection induces host inammatory\nresponses by facilitating NLRP3 inammasome assembly and interleukin-1 β  secretion. Nat\nCommun. 2018;9:106.\n32. Akoum A, Al-Akoum M, Lemay A, Maheux R, Leboeuf M. Imbalance in the peritoneal levels of\ninterleukin 1 and its decoy inhibitory receptor type II in endometriosis women with infertility and\n\nPage 16/28\npelvic pain. Fertil Steril. 2008;89:1618–24.\n33. Peng B, Alotaibi FT, Sediqi S, Bedaiwy MA, Yong PJ. Role of interleukin-1 β  in nerve growth factor\nexpression, neurogenesis and deep dyspareunia in endometriosis. Hum Reprod. 2020;35:901–12.\n34. Mita S, Shimizu Y, Sato A, Notsu T, Imada K, Kyo S. Dienogest inhibits nerve growth factor expression\ninduced by tumor necrosis factor- α  or interleukin-1 β . Fertil Steril. 2014;101:595–601.\n35. Liu Y, Zhang Z, Lu X, Meng J, Qin X, Jiang J. Anti-nociceptive and anti-inammatory effects of\nsulforaphane on sciatic endometriosis in a rat model. Neurosci Lett. 2020;723:134858.\n3. Nie K, Li J, Peng L, Zhang M, Huang W. Pan-Cancer Analysis of the Characteristics of LY96 in\nPrognosis and Immunotherapy Across Human Cancer. Front Mol Biosci. 2022;9:837393.\n37. Mo H-Q, Tian F-J, Ma X-L, Zhang Y-C, Zhang C-X, Zeng W-H, et al. PDIA3 regulates trophoblast\napoptosis and proliferation in preeclampsia via the MDM2/p53 pathway. Reproduction.\n2020;160:293–305.\n3. Tu Z, Ouyang Q, Long X, Wu L, Li J, Zhu X, et al. Protein Disulde-Isomerase A3 Is a Robust\nPrognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively. Front\nImmunol. 2022;13:837512.\n39. Hever A, Roth RB, Hevezi P, Marin ME, Acosta JA, Acosta H, et al. Human endometriosis is associated\nwith plasma cells and overexpression of B lymphocyte stimulator. Proc Natl Acad Sci U S A.\n2007;104:12451–6.\n40. Xiang R, Chen P, Zeng Z, Liu H, Zhou J, Zhou C, et al. Transcriptomic analysis shows that surgical\ntreatment is likely to inuence the endometrial receptivity of patients with stage III/IV endometriosis.\nFront Endocrinol (Lausanne). 2022;13:932339.\n41. Yunna C, Mengru H, Lei W, Weidong C. Macrophage M1/M2 polarization. Eur J Pharmacol.\n2020;877:173090.\n42. Zhong Q, Yang F, Chen X, Li J, Zhong C, Chen S. Patterns of Immune Inltration in Endometriosis and\nTheir Relationship to r-AFS Stages. Front Genet. 2021;12:631715.\n43. Je M, Sh A, Rm M, Sp M, At F, M K, et al. IL-17A Modulates Peritoneal Macrophage Recruitment and\nM2 Polarization in Endometriosis. Frontiers in immunology [Internet]. Front Immunol; 2020 [cited\n2022 Oct 19];11.\n44. Laganà AS, Salmeri FM, Ban Frange ž  H, Ghezzi F, Vrta č nik-Bokal E, Granese R. Evaluation of M1 and\nM2 macrophages in ovarian endometriomas from women affected by endometriosis at different\nstages of the disease. Gynecol Endocrinol. 2020;36:441–4.\n45. Sugamata M, Ihara T, Uchiide I. Increase of activated mast cells in human endometriosis. Am J\nReprod Immunol. 2005;53:120–5.\n4. Guo X, Xu X, Li T, Yu Q, Wang J, Chen Y, et al. NLRP3 Inammasome Activation of Mast Cells by\nEstrogen via the Nuclear-Initiated Signaling Pathway Contributes to the Development of\nEndometriosis. Front Immunol. 2021;12:749979.\n\nPage 17/28\n47. Anaf V, Chapron C, El Nakadi I, De Moor V, Simonart T, Noël J-C. Pain, mast cells, and nerves in\nperitoneal, ovarian, and deep inltrating endometriosis. Fertil Steril. 2006;86:1336–43.\n4. Binda MM, Donnez J, Dolmans M-M. Targeting mast cells: a new way to treat endometriosis. Expert\nOpin Ther Targets. 2017;21:67–75.\n49. Blumenthal RD, Samoszuk M, Taylor AP, Brown G, Alisauskas R, Goldenberg DM. Degranulating\neosinophils in human endometriosis. Am J Pathol. 2000;156:1581–8.\n50. Eidukaite A, Tamosiunas V. Activity of eosinophils and immunoglobulin E concentration in the\nperitoneal uid of women with endometriosis. Clin Chem Lab Med. 2004;42:590–4.\n51. Chen W, Mook RA, Premont RT, Wang J. Niclosamide: Beyond an antihelminthic drug. Cell Signal.\n2018;41:89–96.\n52. Shi M, Sekulovski N, Whorton AE, MacLean JA, Greaves E, Hayashi K. Ecacy of niclosamide on the\nintra ‐ abdominal inammatory environment in endometriosis. FASEB j [Internet]. 2021 [cited 2022 Oct\n20];35.\nTable 1\nTable 1. Predictive top 10 pharmacologic agent candidates for EMS with NLRP3 activation.\n\nPage 18/28\nDrug name Padj OddsRatio CombinedScore Genes\nTriclocarban CTD 00000497 0.00 713.14 8021.85910 IL1B;NLRP3\nchlorhexidine CTD 00005633 0.00 498.90 5271.69962 IL1B;NLRP3\nuric acid CTD 00006967 0.00 498.90 5271.69962 IL1B;NLRP3\nGNF-Pf-4325 BOSS 0.00 486.71 5119.715195 IL1B;NLRP3\nniclosamide BOSS 0.00 464.02 4838.479209 IL1B;NLRP3\n9-Methoxyellipticine TTD 00001373 0.00 464.02 4838.479209 IL1B;NLRP3\nniclosamide 0.00 415.58 4245.007066 IL1B;NLRP3\nchlorhexidine 0.00 415.58 4245.007066 IL1B;NLRP3\n5H-quinolino[8,7-c][1,2]benzothiazine 6,6-dioxideTTD 00001179 0.00 398.92 4043.246313 IL1B;NLRP3\nthimerosal BOSS 0.00 332.27 3249.969098 IL1B;NLRP3\n \nFigures\n\n\nPage 19/28\nFigure 1\nThe workow of the analysis\nFigure 2\n\nPage 20/28\nThe dysregulated genes were shown in the (A) boxplot and (B) heat map via analyzing GSE7307\ndatasets. 14 DEGs were identied between EMS samples and normal samples.\nFigure 3\n(A) GO and (B) KEGG pathway analyses of 14 DEGs in EMS.\n\nPage 21/28\nFigure 4\nSelection procedure of diagnostic markers for EMS diagnoses.  (A) An illustration of biological marker\nscreening through the SVM-RFE arithmetic. (B)Tuning feature selection in the random forest model. (C)\nAnalyze the meaning of NLRP3 activation-related genes using the scores returned by the random forest\nmodel. (D) Venn graph presenting 4 diagnostic biomarkers shared by the random forest and SVM-RFE\narithmetic methods.\n\nPage 22/28\nFigure 5\nThe expression of four biomarkers in EMS and the diagnostic value of four biomarkers in GSE7307 were\nstudied by ROC analysis. (A) NLRP3, IL-1 Β , and LY96 were highly expressed in EMS. PDIA3 was lowly\nexpressed in EMS. (B)The diagnostic value of the 4 biomarkers was studied using ROC assays in\nGSE7307.\n\nPage 23/28\nFigure 6\nResults of differential gene expression of NLRP3, LY96, IL-1 β  and PDIA3 at the protein level between EMS\nand control samples. (A) Western blotting results. (B) Densitometry of the western blot. N=6 each group.\n*P<0.05 and **P<0.01.\n\nPage 24/28\nFigure 7\nROC curve analysis of the model EMS in the validation datasets (GSE7305 and GSE23339).\n\nPage 25/28\nFigure 8\nIdentication of NLRP3 activation-related genes. (A) Boxplots of the residuals of the sample. Red dot\nstands for root mean square of residuals. (B) Cumulative residual distribution map of the sample. (C) The\nAUC value of the ROC curve indicated that the accuracy of GLM model (0.933) was the highest among\nthe four models. (D) The ROC curve assesses the accuracy of the four models in the validation datasets\n(GSE7305 and GSE23339).\n\nPage 26/28\nFigure 9\nGSEA revealed the enriched pathways of four biomarkers. (A)NLRP3, (B) IL-1 Β , (C) LY96, and (D)PDIA3.\n\nPage 27/28\nFigure 10\nImmune inltration and immune-related factors. (A)The number of immune cells in each EMS sample is\nrepresented by a different color. (B) Differences of the inltrate immune cells between the normal (blue)\nand EMS (red) groups. (C) Heat map of correlation of four biomarkers (NLRP3, IL-1B, LY96, and PDIA3)\nwith 22 immune cell subsets. (D) Correlation between NLRP3, IL-1B, LY96, and PDIA3 and inltrating\nimmune cells in EMS.\n\nPage 28/28\nFigure 11\nConstruction and assessment of a nomogram model for EMS diagnosis based on the training set. (A)\nNomogram to predict the occurrence of EMS. (B)Calibration curve to assess the predictive power of the\nnomogram model. (C) Decision curve analysis (DCA) to evaluate the clinical value of the nomogram\nmodel.","source_license":"CC-BY-4.0","license_restricted":false}